Metabolic Dependencies in Pancreatic Cancer

Ali Vaziri-Gohar, Mahsa Zarei, Jonathan R Brody, Jordan M Winter, Ali Vaziri-Gohar, Mahsa Zarei, Jonathan R Brody, Jordan M Winter

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy. FDA approved drugs currently used against PDA target DNA metabolism and DNA integrity. However, alternative metabolic targets beyond DNA may prove to be much more effective. PDA cells are forced to live within a particularly severe microenvironment characterized by relative hypovascularity, hypoxia, and nutrient deprivation. Thus, PDA cells must possess biochemical flexibility in order to adapt to austere conditions. A better understanding of the metabolic dependencies required by PDA to survive and thrive within a harsh metabolic milieu could reveal specific metabolic vulnerabilities. These molecular requirements can then be targeted therapeutically, and would likely be associated with a clinically significant therapeutic window since the normal tissue is so well-perfused with an abundant nutrient supply. Recent work has uncovered a number of promising therapeutic targets in the metabolic domain, and clinicians are already translating some of these discoveries to the clinic. In this review, we highlight mitochondria metabolism, non-canonical nutrient acquisition pathways (macropinocytosis and use of pancreatic stellate cell-derived alanine), and redox homeostasis as compelling therapeutic opportunities in the metabolic domain.

Keywords: metabolic dependencies; metabolism; pancreatic cancer; redox homeostasis; targeting metabolism.

Figures

Figure 1
Figure 1
Pancreatic ductal adenocarcinoma. (A) Resected human PDA. The arrow identifies the characteristically pale, gray, and hypovascular pancreatic ductal adenocarcinoma. The asterisk marks pancreatic parenchyma. (B) On CT scan imaging with intravenous contrast, PDA appears hypodense (dark gray), while well-perfused normal pancreatic parenchyma shows bright enhancement due to penetration by the contrast.
Figure 2
Figure 2
Metabolic features in PDA cells under nutrient abundance and deprivation. Under nutrient abundance, PDA cells have a proliferative phenotype and macromolecular synthesis is prioritized over ATP generation. Under nutrient deprivation, PDA cells have a survival phenotype, and nutrient conservation with maximal ATP generation are prioritized. OXPHOS, oxidative phosphorylation.
Figure 3
Figure 3
Intrinsic and extrinsic nutrient acquisition pathways in PDA cells. PDA cells hijack stromal elements to fuel the tricarboxylic acid (anaplerosis) and other biochemical processes when nutrients are limited. Carbon is extracted by macropinocytosis (A) and autophagy (B) after auto-digestion by lysosomes. PDA cells also stimulate pancreatic stellate cells to produce and excrete free alanine (C). Non-functional mitochondria are dark in the figure and are targeted for autophagy. Functional mitochondria are colored pink. TCA, tricarboxylic acid.
Figure 4
Figure 4
Signaling pathways that restore redox homeostasis in PDA. Nutrient scarcity in the PDA microenvironment augments oxidative stress. Multiple adaptive strategies are recruited by PDA cells. KRAS signaling promotes NADPH production through glutamine catabolism, followed by ME1 activity. In addition, NRF2 and NADK are upregulated. HuR cytoplasmic translocation stabilizes IDH to enhance reductive power. GLS, glutaminase; GOT, aspartate transaminase; ME1, malic enzyme 1; IDH1, isocitrate dehydrogenase 1; TCA, tricarboxylic acid; ROS, reactive oxygen species; NADK, NAD+ kinase.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018) 68:7–30. 10.3322/caac.21442
    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. (2014) 74:2913–21. 10.1158/0008-5472.CAN-14-0155
    1. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). (2004) 16:549–60. 10.1016/j.clon.2004.06.007
    1. Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol. (2007) 25:1949–52. 10.1200/JCO.2006.09.4664
    1. Ren C, Chen H, Han C, Jin G, Wang D, Tang D. Detection and molecular analysis of circulating tumor cells for early diagnosis of pancreatic cancer. Med Hypotheses (2013) 80:833–6. 10.1016/j.mehy.2013.03.027
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. (2010) 362:1605–17. 10.1056/NEJMra0901557
    1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet (2011) 378:607–20. 10.1016/S0140-6736(10)62307-0
    1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet (2004) 363:1049–57. 10.1016/S0140-6736(04)15841-8
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. (2013) 369:1691–703. 10.1056/NEJMoa1304369
    1. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 32:5253–60. 10.1038/onc.2013.29
    1. Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, et al. . Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. (2016) 6:166–75. 10.1158/-15-0402
    1. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature (1999) 400:464–8. 10.1038/22780
    1. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, et al. . Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA. (2006) 103:5947–52. 10.1073/pnas.0601273103
    1. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. (2002) 19:607–14. 10.1002/humu.10081
    1. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol. (2005) 70:65–72. 10.1101/sqb.2005.70.040
    1. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. . Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 7:469–83. 10.1016/j.ccr.2005.04.023
    1. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell (2002) 2:25–8. 10.1016/S1535-6108(02)00093-4
    1. Winter JM, Maitra A, Yeo CJ. Genetics and pathology of pancreatic cancer. HPB (2006) 8:324–36. 10.1080/13651820600804203
    1. Yabar CS, Winter JM. Pancreatic cancer: a review. Gastroenterol Clin North Am. (2016) 45:429–45. 10.1016/j.gtc.2016.04.003
    1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. (2006) 20:1218–49. 10.1101/gad.1415606
    1. Murthy D, Attri KS, Singh PK. Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. Front Physiol. (2018) 9:335. 10.3389/fphys.2018.00335
    1. Ndlovu R, Deng LC, Wu J, Li XK, Zhang JS. Fibroblast growth factor 10 in pancreas development and pancreatic cancer. Front Genet. (2018) 9:482. 10.3389/fgene.2018.00482
    1. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg. (2006) 13:286–95. 10.1007/s00534-005-1057-1
    1. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. (2012) 18:4266–76. 10.1158/1078-0432.CCR-11-3114
    1. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. (2010) 32:128–31.
    1. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 21:418–29. 10.1016/j.ccr.2012.01.007
    1. Xie K, Huang S. Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis (2003) 20:31–43. 10.1023/A:1022590402748
    1. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (1988) 240:177–84.
    1. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. . Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 149:656–70. 10.1016/j.cell.2012.01.058
    1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029–33. 10.1126/science.1160809
    1. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. (1927) 8:519–30.
    1. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, et al. . Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. (2013) 110:3919–24. 10.1073/pnas.1219555110
    1. Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. . Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol. (2007) 30:849–55. 10.3892/ijo.30.4.849
    1. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, et al. . Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. (2001) 61:6548–54.
    1. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. . Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature (2013) 497:633–7. 10.1038/nature12138
    1. Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J, et al. . A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res. (2014) 20:4370–80. 10.1158/1078-0432.CCR-14-0186
    1. Payen VL, Porporato PE, Baselet B, Sonveaux P. Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell Mol Life Sci. (2016) 73:1333–48. 10.1007/s00018-015-2098-5
    1. Hume DA, Weidemann MJ. Role and regulation of glucose metabolism in proliferating cells. J Natl Cancer Inst. (1979) 62:3–8.
    1. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. (2011) 27:441–64. 10.1146/annurev-cellbio-092910-154237
    1. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP, et al. . Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem. (1999) 274:20281–6.
    1. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, et al. . Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol. (2013) 9:712. 10.1038/msb.2013.65
    1. Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, et al. . Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun. (2017) 8:14437. 10.1038/ncomms14437
    1. Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al. . MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci USA. (2012) 109:13787–92. 10.1073/pnas.1203339109
    1. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol. (2007) 19:223–9. 10.1016/j.ceb.2007.02.003
    1. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. (2006) 3:177–85. 10.1016/j.cmet.2006.02.002
    1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. (2008) 7:11–20. 10.1016/j.cmet.2007.10.002
    1. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim Biophys Acta (2011) 1807:552–61. 10.1016/j.bbabio.2010.10.012
    1. Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (Review). Oncol Lett. (2012) 4:1151–7. 10.3892/ol.2012.928
    1. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. (2004) 64:985–93. 10.1158/0008-5472.CAN-03-1101
    1. Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, et al. . Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res. (2017) 77:4460–71. 10.1158/0008-5472.CAN-17-0015
    1. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, et al. . Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature (2014) 508:108–12. 10.1038/nature13110
    1. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. (2014) 87:20130676. 10.1259/bjr.20130676
    1. Rumsey WL, Schlosser C, Nuutinen EM, Robiolio M, Wilson DF. Cellular energetics and the oxygen dependence of respiration in cardiac myocytes isolated from adult rat. J Biol Chem. (1990) 265:15392–402.
    1. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. (2015) 11:9–15. 10.1038/nchembio.1712
    1. Schroeder T, Yuan H, Viglianti BL, Peltz C, Asopa S, Vujaskovic Z, et al. . Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res. (2005) 65:5163–71. 10.1158/0008-5472.CAN-04-3900
    1. Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, et al. . HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol. (2013) 10:1312–23. 10.4161/rna.25274
    1. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. . Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 496:101–5. 10.1038/nature12040
    1. Gao AW, Cantó C, Houtkooper RH. Mitochondrial response to nutrient availability and its role in metabolic disease. EMBO Mol Med. (2014) 6:580–9. 10.1002/emmm.201303782
    1. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. (2013) 17:491–506. 10.1016/j.cmet.2013.03.002
    1. Molina AJ, Wikstrom JD, Stiles L, Las G, Mohamed H, Elorza A, et al. . Mitochondrial networking protects beta-cells from nutrient-induced apoptosis. Diabetes (2009) 58:2303–15. 10.2337/db07-1781
    1. Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci USA. (2011) 108:10190–5. 10.1073/pnas.1107402108
    1. Li X, Li T, Liu Z, Gou S, Wang C. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep. (2017) 7:5825. 10.1038/s41598-017-06207-x
    1. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A, et al. . Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. (2015) 16:839–47. 10.1016/S1470-2045(15)00027-3
    1. Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, et al. . (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res. (2016) 22:1076–85. 10.1158/1078-0432.CCR-15-1722
    1. Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, et al. A phase II clinical trial of CPI-613 in patients with relapsed or refractory small cell lung carcinoma. PLoS ONE (2016) 11:e0164244 10.1371/journal.pone.0164244
    1. Egawa Y, Saigo C, Kito Y, Moriki T, Takeuchi T. Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma. PLoS ONE (2018) 13:e0198940. 10.1371/journal.pone.0198940
    1. Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, et al. . Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. (2017) 18:770–8. 10.1016/S1470-2045(17)30314-5
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. (2011) 364:1817–25. 10.1056/NEJMoa1011923
    1. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. (2009) 43:67–93. 10.1146/annurev-genet-102808-114910
    1. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell (2010) 140:313–26. 10.1016/j.cell.2010.01.028
    1. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol. (2010) 12:814–22. 10.1038/ncb0910-814
    1. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer (2012) 12:401–10. 10.1038/nrc3262
    1. Gohar AV, Cao R, Jenkins P, Li W, Houston JP, Houston KD. Subcellular localization-dependent changes in EGFP fluorescence lifetime measured by time-resolved flow cytometry. Biomed Opt Express. (2013) 4:1390–400. 10.1364/BOE.4.001390
    1. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. . Pancreatic cancers require autophagy for tumor growth. Genes Dev. (2011) 25:717–29. 10.1101/gad.2016111
    1. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, Kojima M, et al. . Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. (2008) 99:1813–9. 10.1111/j.1349-7006.2008.00893.x
    1. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. . Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. (2011) 25:460–70. 10.1101/gad.2016311
    1. Magni G, Amici A, Emanuelli M, Raffaelli N, Ruggieri S. Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol. (1999) 73:135–82, xi.
    1. Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, et al. . Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. (2016) 379:1–11. 10.1016/j.canlet.2016.05.024
    1. Chini CC, Guerrico AM, Nin V, Camacho-Pereira J, Escande C, Barbosa MT, et al. . Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res. (2014) 20:120–30. 10.1158/1078-0432.CCR-13-0150
    1. Espindola-Netto JM, Chini CCS, Tarragó M, Wang E, Dutta S, Pal K, et al. . Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget (2017) 8:85054–67. 10.18632/oncotarget.18841
    1. Sidaway P. Pancreatic cancer: pancreatic cancer cells digest extracellular protein. Nat Rev Clin Oncol. (2017) 14:138. 10.1038/nrclinonc.2017.3
    1. Perera RM, Bardeesy N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. (2015) 5:1247–61. 10.1158/-15-0671
    1. Bar-Sagi D, Feramisco JR. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science (1986) 233:1061–8.
    1. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, et al. . Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. (2015) 75:544–53. 10.1158/0008-5472.CAN-14-2211
    1. Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. . Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 536:479–83. 10.1038/nature19084
    1. Liou GY, Döppler H, DelGiorno KE, Zhang L, Leitges M, Crawford HC, et al. . Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. Cell Rep. (2016) 14:2325–36. 10.1016/j.celrep.2016.02.029
    1. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. . Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. (2010) 107:8788–93. 10.1073/pnas.1003428107
    1. Sullivan LB, Chandel NS. Mitochondrial reactive oxygen species and cancer. Cancer Metab. (2014) 2:17. 10.1186/2049-3002-2-17
    1. Feig DI, Reid TM, Loeb LA. Reactive oxygen species in tumorigenesis. Cancer Res. (1994) 54(7 Suppl.):1890s−4s.
    1. Khramtsov VV, Gillies RJ. Janus-faced tumor microenvironment and redox. Antioxid Redox Signal. (2014) 21:723–9. 10.1089/ars.2014.5864
    1. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem. (2005) 280:4254–63. 10.1074/jbc.M411662200
    1. Chio IIC, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med. (2017) 23:411–29. 10.1016/j.molmed.2017.03.004
    1. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Rad Biol Med. (1990) 8:15–9.
    1. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. (2000) 60:6201–7.
    1. Policastro LL, Ibanez IL, Notcovich C, Duran HA, Podhajcer OL. The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid Redox Signal. (2013) 19:854–95. 10.1089/ars.2011.4367
    1. Yang S, Hwang S, Kim M, Seo SB, Lee JH, Jeong SM. Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition. Cell Death Dis. (2018) 9:55. 10.1038/s41419-017-0089-1
    1. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. . Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 475:106–9. 10.1038/nature10189
    1. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. (2014) 39:199–218. 10.1016/j.tibs.2014.02.002
    1. Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. (2017) 29:1727–45. 10.1089/ars.2017.7342
    1. Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, et al. . Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun. (2016) 7:10500. 10.1038/ncomms10500
    1. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. (2012) 48:158–67. 10.1016/j.molcel.2012.09.025
    1. Ciccarese F, Ciminale V. Escaping death: mitochondrial redox homeostasis in cancer cells. Front Oncol. (2017) 7:117. 10.3389/fonc.2017.00117
    1. Braghiroli MI, de Celis Ferrari AC, Pfiffer TE, Alex AK, Nebuloni D, Carneiro AS, et al. . Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience (2015) 9:563. 10.3332/ecancer.2015.563
    1. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. . Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist (2014) 19:637–8. 10.1634/theoncologist.2014-0086
    1. Balic A, Sørensen MD, Trabulo SM, Sainz B, Cioffi M, Vieira CR, et al. . Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol Cancer Ther. (2014) 13:1758–71. 10.1158/1535-7163.MCT-13-0948
    1. Samaras P, Tusup M, Nguyen-Kim TDL, Seifert B, Bachmann H, von Moos R, et al. Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemother Pharmacol. (2017) 80:1005–12. 10.1007/s00280-0173446-y

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir